HIV-infected individuals taking antiretroviral medications may experience changes in body
shape and metabolism, commonly known as HIV-associated lipodystrophy (HIVLD). In vitro …

Background Human immunodeficiency virus (HIV)-associated lipodystrophy is a syndrome
that occurs primarily in individuals who are being treated with highly active antiretroviral …

The HIV-associated lipodystrophy syndrome is one of the major side effects of HIV-therapy.
Its metabolic abnormalities may harbor a significant risk for cardiovascular disease with as …

AIDS: Researchers at the 12th World AIDS Conference in Geneva shared information on
HIV lipodystrophy syndrome (LDS), addressing the difficulty in defining and understanding …

Objective To study the prevalence, clinical characteristics and risk factors of HIV-related
lipodystrophy syndrome (HIV-LD) in our cohort of HIV-1 infected Chinese adults. Methods In …

Potent antiretroviral agents markedly suppress HIV and have dramatically improved the
clinical course, prognosis, and survival of HIV-infected patients. Unfortunately, highly active …

Antiretroviral regimens excluding stavudine and zidovudine offer substantial protection
against lipoatrophy. Established lipoatrophy improves gradually with the cessation of these …

Changes in body fat distribution are frequent findings in HIV/AIDS patients, with onset shortly
after initiation of combination antiretroviral therapy (cART). Lipoatrophy (loss of peripheral …

Lipoatrophy (LA) is a form of lipodystrophy, characterized by volume depletion caused by fat
loss in the limbs, buttocks, and face. Facial volume loss is the most obvious outward sign of …

HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is an
adipose tissue redistribution disorder characterized by subcutaneous adipose tissue …